CXCL13 as a Biomarker in Multiple Sclerosis
Author Information
Author(s): Pachner Andrew R., Pike Steven, Smith Andrew D., Gilli Francesca
Primary Institution: Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center
Hypothesis
CXCL13 has the potential to be an exceptionally useful biomarker in a range of inflammatory diseases.
Conclusion
CXCL13 is a key chemokine in the immune system and is important for the trafficking of B cells and follicular helper T cells.
Supporting Evidence
- CXCL13 levels in the CSF of MS patients are usually between 5 and 100 pg/mL.
- The CXCL13 index outperformed other potential predictive biomarkers in CIS.
- High CXCL13 indices were associated with a higher likelihood of converting to clinically definite MS.
Takeaway
CXCL13 is a special protein that helps doctors understand and treat diseases like multiple sclerosis by showing how the immune system is working.
Methodology
The study utilized matched serum and CSF samples from MS patients and analyzed clinical and imaging activity after lumbar puncture.
Limitations
The study did not create or analyze new data, relying on existing literature and data.
Participant Demographics
Participants included 67 non-inflammatory controls and 67 MS patients.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website